Biotech Values

[mcbio]

SRPT/DMD deals -

Perhaps you may be right about possibly a Summit deal sooner rather than later (if data good) but I am not convinced and still sticking to my thesis (CATB easily fits) smile. If it turns out their next generation stuff doesn't do much better (i.e. they don't try to for Exon 51, 45, 53) at getting to muscle/skeletal cells (cardiac pretty important in DMD) or If they do another big equity offer (in addition to selling PRV) in the next year or so I'd change my thinking.

Even if you look beyond Exondys at the broad current SRPT DMD pipeline, it doesn't not potentially address all DMD patients. I'm not sure if they even get to half of the potential DMD patients with their current full pipeline. And then you have the point that a DMD drug with a different MoA could be additive or synergistic with Exondys and SRPT's other pipeline candidates. So, not all that surprising to me that they plan to look to add other DMD drugs with different MoAs (particularly those that could address all DMD patients).